comparative effectiveness

Research in Review

More Docetaxel Cycles May Improve Prostate Cancer Survival

08/30/2016

JCP Editors

A larger number of docetaxel cycles may improve survival among men with metastatic castration-resistant prostate cancer (mCRPC), according to a post-hoc analysis of phase III clinical trial results. Scientists and...

A...

08/30/2016

Journal of Clinical Pathways

Research in Review

Radiotherapy as Effective as Surgery for Prostate Cancer

08/21/2016

JCP Editors

Radiotherapy and radical prostatectomy resulted in similar survival outcomes among men with aggressive prostate cancer, according to the results of a comparative analysis published in European Urology. Currently,...

...

08/21/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz ‚Äì Week of August 15-21

08/18/2016

JCP Editors

A recent study of non-small cell lung cancer found that those with epidermal growth factor receptor (EGFR)-positive disease were at an increased likelihood of developing leptomeningeal metastases (LM), but that...

A...

08/18/2016

Journal of Clinical Pathways

Research in Review

Leptomeningeal Metastases More Common in EGFR+ Lung Cancer

08/17/2016

JCP Editors

Leptomeningeal metastases (LM) incidence is far more common in patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations and is best treated with targeted tyrosine kinase...

...

08/17/2016

Journal of Clinical Pathways

Research in Review

ESR1 Mutations May Affect Treatment for Metastatic Breast Cancer

08/16/2016

JCP Editors

Estrogen receptor α (ESR1) mutations are highly prevalent in women receiving aromatase inhibitors for metastatic breast cancer (MBC), according to a secondary analysis from a clinical trial. ESR1 mutations found in...

...

08/16/2016

Journal of Clinical Pathways

Research in Review

Bortezomib Regimen More Cost Effective Than Current Standard for Mantle Cell Lymphoma

08/05/2016

JCP Editors

Bortezomib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (VR-CAP) may be a more cost-effective treatment option in the United Kingdom for patients with previously untreated mantle cell...

...

08/05/2016

Journal of Clinical Pathways

Research in Review

Immunotherapy Plus Chemotherapy Does not Improve SCLC Outcomes

08/05/2016

JCP Editors

The addition of ipilimumab to etoposide and a platinum agent failed to demonstrate improved survival in patients with extensive-stage small-cell lung cancer when compared with chemotherapy alone, a study published in...

The...

08/05/2016

Journal of Clinical Pathways

Quiz

Friday Morning Quiz ‚Äì Week of August 1-7

08/04/2016

JCP Editors

Results of a phase III study assessing the effectiveness of biosimilar ABP 980 found that it was not inferior to which of the following drugs for the treatment of human epidermal growth factor receptor 2...

...

08/04/2016

Journal of Clinical Pathways

Research in Review

Equivalent Outcomes With Two NSCLC Treatment Options

08/04/2016

JCP Editors

Erlotinib may be an effective therapeutic option for patients with pretreated advanced non-small cell lung cancer (NSCLC) and no known molecular alterations, according to a study published in the journal Lung...

...

08/04/2016

Journal of Clinical Pathways

Research in Review

Radiotherapy Use and Effectiveness in Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma

08/02/2016

JCP Editors

A study of adjuvant chemoradiotherapy (CRT) and boost doses of postoperative radiotherapy (B-PORT) in oropharyngeal squamous cell carcinoma (OSCC) has found that outcomes depend on a number of pathologic and...

...

08/02/2016

Journal of Clinical Pathways